Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Arcellx

In-Depth Examination Of 14 Analyst Recommendations For Arcellx

In the last three months, 14 analysts have published ratings on Arcellx (NASDAQ:ACLX), offering a diverse range of perspectives from bullish to bearish.

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.

Investors Business Daily

14 Analysts Have This To Say About Arcellx

14 Analysts Have This To Say About Arcellx

In the latest quarter, 14 analysts provided ratings for Arcellx (NASDAQ:ACLX), showcasing a mix of bullish and bearish perspectives.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

2 Potential Stocks to Buy From Barchart’s ‘Death Cross’ Indicator

While a security’s short-term moving average dipping below its long-term average warrants caution, this dynamic may also be a contrarian indicator.

Arcellx Stock Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Arcellx shows improving technical performance.

Investors Business Daily

GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

These Stocks Are Exploding In The November Stock Market Rally

The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Jumps Another 160 Points Amid More Evidence Inflation Is Waning

Dow Jones Jumps Another 160 Points Amid More Evidence Inflation Is Waning

After a red letter day on the stock market, investor enthusiasm kept climbing on the Dow Jones index as all major indexes piled on gains.

Investors Business Daily

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx and Gilead's Kite division deepened their collaboration in cancer treatments on Wednesday. ACLX stock rocketed into a breakout.

Investors Business Daily

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death

The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday.

Investors Business Daily

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences

Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

More Than $6 Million Bet On JELD-WEN Holding? 3 Stocks Insiders are Buying

More Than $6 Million Bet On JELD-WEN Holding? 3 Stocks Insiders are Buying

Although the US stocks closed higher on Thursday, there were a few notable insider trades.

How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer

How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer

Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Expert Ratings for Arcellx

Analysts have provided the following ratings for Arcellx (NASDAQ:ACLX) within the last quarter:

Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma

Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).

BofA Initiates Arcellx With Buy On Its Novel Therapy Approach

Arcellx (NASDAQ: ACLX) is advancing into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known as ddBCMA, for relapsed refractory multiple myeloma, according to BofA Securities.

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Get all your
news in one place.

100’s of premium titles.
One news app.

CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19

CAR-T company Arcellx Inc (NASDAQ: ACLX) priced its IPO at

1

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

Johnson & Johnson (

Advanced Micro Devices

Paramount Global

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

243,722 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play